1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Aug 2023
Admin
News Article

Phebra and University of Wollongong Enter into Collaboration Agreement

Phebra and the University of Wollongong have entered into a new six-year collaboration agreement. This collaboration aims to further advance promising research and development (R&D) endeavours, including clinical trials, focused on patented and targeted arsenic compounds.

This collaboration not only emphasises the creation of new drugs but also the local production and commercialisation of essential medical solutions. Moreover, this extended collaboration further indicates the progress and potential of the research, with the anticipation of moving the developed drug into human trials.

This extended collaboration underscores Phebra's commitment to addressing critical unmet medical needs and actively pursuing the development, local manufacturing, and commercialisation of essential products.Through its partnership with UOW, Phebra aims to introduce novel pharmaceuticals that cater to significant unmet medical requirements.

The recently developed molecule employs a precision targeting system for the controlled delivery of minute quantities of its active component, arsenic, exclusively to predetermined cancer cells.

This innovative approach aims to minimise the occurrence of unintended side effects in non-target cells, thus broadening the drug's therapeutic applicability to challenging-to-treat cancer types. Favourable results have been observed in the case of acute myeloid leukaemia (AML) and pancreatic cell lines, indicating promising outcomes for the drug.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!